GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Total Stockholders Equity

Novaccess Global (Novaccess Global) Total Stockholders Equity : $-6.85 Mil (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global Total Stockholders Equity?

Novaccess Global's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-6.85 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Novaccess Global's Book Value per Share for the quarter that ended in Mar. 2024 was $-0.22. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Novaccess Global's Debt-to-Equity for the quarter that ended in Mar. 2024 was -0.32.

Novaccess Global Total Stockholders Equity Historical Data

The historical data trend for Novaccess Global's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global Total Stockholders Equity Chart

Novaccess Global Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.24 -3.57 -3.93 -4.65 -7.80

Novaccess Global Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.73 -6.23 -7.80 -6.43 -6.85

Novaccess Global  (OTCPK:XSNX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Novaccess Global's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.854-0)/30.512
=-0.22

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Novaccess Global's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.165 + 0) / -6.854
=-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novaccess Global Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Novaccess Global's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Novaccess Global (Novaccess Global) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Total Stockholders Equity
Comparable Companies
BLPH ISCO HSTO SQZB IPIX ENDV MSSV BTTX BXRXQ GSTC OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
N/A
Address
8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Website
https://www.novaccessglobal.com
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404